Regdanvimab vs placebo
Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Regdanvimab showed no clear difference in admission to hospital or death by day 30Â compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyRR 0.45 [0.14, 1.42]1 study · 204 participantsLow